Reply to thread

Message

[QUOTE="Munyaradzi Mafaro, post: 35209, member: 636"]
Research shows that two moxifloxacin versions taste better than generic alternatives for children with tuberculosis. The ChilPref ML study comes from Stellenbosch University, working with the TB Alliance, and is funded through Unitaid. Scientists have improved treatments for drug-resistant TB, which used to be extremely hard to manage with few child-friendly options. They focused on making medicines more palatable, which parents say matters greatly when treating children.

Moxifloxacin serves as one component in the four-drug BPaLM treatment for multidrug-resistant tuberculosis. Doctors prescribe this combination when TB resists standard first-line drugs like rifampicin or rifampicin with isoniazid. About 25,000 to 32,000 children under 15 develop these resistant TB strains each year worldwide. These young patients react strongly to medicine flavors.

Treatment for resistant TB runs six to nine months, creating challenges for parents dealing with bitter medicines. The study proved their approach works safely at a low cost. Researchers engaged children directly about their taste preferences for medications. This method could help with other TB drugs and different diseases. Making medicines easier for children increases successful treatment completion rates, addressing needs often overlooked because they require extra attention.
[/QUOTE]

Name